Pathway Health Third Quarter 2022 Earnings: CA$0.021 loss per share (vs CA$0.034 loss in 3Q 2021)




  • In Business
  • 2022-11-26 12:32:49Z
  • By Simply Wall St.
 

Pathway Health (CVE:PHC) Third Quarter 2022 Results

Key Financial Results

  • Revenue: CA$2.42m (down 9.4% from 3Q 2021).

  • Net loss: CA$1.92m (loss narrowed by 39% from 3Q 2021).

  • CA$0.021 loss per share (improved from CA$0.034 loss in 3Q 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pathway Health's share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for Pathway Health (4 are a bit unpleasant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

The science behind the zombie fungus from
The science behind the zombie fungus from 'The Last of Us'

The hit HBO series "The Last Of Us" describes a post-pandemic world devastated by a mass outbreak of a "zombie fungus" that infects and takes over the mind of its hosts. Cordyceps - the so-called "zombie fungus" - is a real fungus and is sometimes used in treatments and therapeutics in Chinese herbal medicine. Although cordyceps does not infect humans, it does infect a wide range of insects.

LifeVantage Second Quarter 2023 Earnings: US$0.084 loss per share (vs US$0.006 profit in 2Q 2022)
LifeVantage Second Quarter 2023 Earnings: US$0.084 loss per share (vs US$0.006 profit in 2Q 2022)

LifeVantage ( NASDAQ:LFVN ) Second Quarter 2023 Results Key Financial Results Revenue: US$53.7m (up 2.8% from 2Q 2022...

CONMED Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
CONMED Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

CONMED ( NYSE:CNMD ) Full Year 2022 Results Key Financial Results Revenue: US$1.05b (up 3.4% from FY 2021). Net loss...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business